Pharsight

Drugs that contain Dasatinib

1. Phyrago patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324745 NANOCOPOEIA Amorphous solid dispersions of dasatinib and uses thereof
Jan, 2041

(16 years from now)

US11202778 NANOCOPOEIA Amorphous solid dispersions of dasatinib and uses thereof
Jan, 2041

(16 years from now)

US11298356 NANOCOPOEIA Amorphous solid dispersions of dasatinib and uses thereof
Jan, 2041

(16 years from now)

Market Authorisation Date: 05 December, 2023

Treatment: Use of dasatinib for treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib, when administered at ...

Dosage: TABLET;ORAL

More Information on Dosage

PHYRAGO family patents

Family Patents

2. Sprycel patents expiration

SPRYCEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(11 months from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(1 year, 5 months from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2025
Pediatric Exclusivity (PED) Jun 21, 2026

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage

SPRYCEL family patents

Family Patents